<DOC>
	<DOCNO>NCT02581020</DOCNO>
	<brief_summary>This study seek assess durability response persistence resistance ombitasvir/ paritaprevir/ritonavir Japanese participant enrol Phase 2 3 clinical study agent treatment chronic hepatitis C .</brief_summary>
	<brief_title>The Durability Response Persistence Resistance AbbVie 's 2 Direct-acting Antiviral Agent ( 2D ) Therapy Japanese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Participants treat Study M12536 M13004 2D regimen ( ombitasvir/ paritaprevir/ ritonavir ) complete 48 week followup , regardless SVR achievement . Participants agree sign inform consent Participants treat directacting antiviral agent ( DAA ) immediately Study M12536 M13004 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Observation</keyword>
	<keyword>Japanese</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Follow-up</keyword>
</DOC>